Pharmaceutical Sciences and Natural Products - Research Publications
Permanent URI for this collectionhttps://kr.cup.edu.in/handle/32116/56
Browse
9 results
Search Results
Item A review on reported phytochemicals as druggable leads with antimalarial potential(Springer, 2023-07-04T00:00:00) Guchait, Avishek; Kumar, Asim; Singh, Roopam; Joshi, Gaurav; Dwivedi, Ashish RanjanThe science and practice of drug discovery and development is primarily benefitted from the natural sources. The chemistry of natural products has inspired medicinal chemists to develop and design various therapeutic molecules from the leads obtained from natural sources. This is evident from the growing number of publications on natural products derived from drug molecules. Some of the most successful bioactive natural product candidates so far are Taxol obtained from �Taxus Brevifolia,� Quinine obtained from the bark of the cinchona plant, morphine obtained from the dried latex of the poppy plant, Vincristine, and Vinblastine from �Vinca Rosea,� atropine from �Atropa Belladonna�, Digoxin and Digitoxin from �Digitalis Purpurea� and Artemisinin from �Artemisia Annua�. Parasitic pathogens are one of the significant menaces for the world as they lead to various diseases in hosts, and for many diseases, these parasite compromises the host�s immune system. Malaria is a parasitic disease especially endemic to tropical countries and is one of the leading causes of death worldwide. According to the latest data from WHO, millions of patients are suffering from malaria and its related complications on 30th March 2022. Natural products derived leads have brought a paradigm shift in the discovery of antimalarial drugs. The first antimalarial drug, quinine, was isolated from the Cinchona species (Family: Rubiaceae) in 1820 and is still used today. This was followed by another antimalarial drug a century later, chloroquine, discovered in the 1940s. After that, Artemisinin was founded in 1972 by Tu Youyou, co-recipient of the 2015 Nobel Prize in Medicine for her discovery. Unfortunately, the malarial parasite, mainly Plasmodium falciparum, develops resistance to these drugs, and thus there exists a need to explore other natural herbs for their role as antimalarials. The current review is therefore kept forth to congregate updated information on undergoing research in allied areas of natural product-based drug discovery, particularly for developing antimalarial agents. � 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.Item Virtual screening and molecular dynamics simulation approach for the identification of potential multi-target directed ligands for the treatment of Alzheimer�s disease(Taylor and Francis Ltd., 2023-04-28T00:00:00) Jangid, Kailash; Devi, Bharti; Sahoo, Ashrulochan; Kumar, Vijay; Dwivedi, Ashish Ranjan; Thareja, Suresh; Kumar, Rajnish; Kumar, VinodAlzheimer�s disease (AD) is a multifactorial neurological disorder characterized by memory loss and cognitive impairment. The currently available single-targeting drugs have miserably failed in the treatment of AD, and multi-target directed ligands (MTDLs) are being explored as an alternative treatment strategy. Cholinesterase and monoamine oxidase enzymes are reported to play a crucial role in the pathology of AD, and multipotent ligands targeting these two enzymes simultaneously are under various phases of design and development. Recent studies have revealed that computational approaches are robust and trusted tools for identifying novel therapeutics. The current research work is focused on the development of potential multi-target directed ligands that simultaneously inhibit acetylcholinesterase (AChE) and monoamine oxidase B (MAO-B) enzymes employing a structure-based virtual screening (SBVS) approach. The ASINEX database was screened after applying pan assay interference and drug-likeness filter to identify novel molecules using three docking precision criteria; High Throughput Virtual Screening (HTVS), Standard Precision (SP), and Extra Precision (XP). Additionally, binding free energy calculations, ADME, and molecular dynamic simulations were employed to get structural insights into the mechanism of protein-ligand binding and pharmacokinetic properties. Three lead molecules viz. AOP19078710, BAS00314308 and BDD26909696 were successfully identified with binding scores of ?10.565, ?10.543 & ?8.066 kcal/mol against AChE and ?11.019, ?12.357 & ?10.068 kcal/mol against MAO-B, better score as compared to the standard inhibitors. In the near future, these molecules will be synthesized and evaluated through in�vitro and in�vivo assays for their inhibition potential against AChE and MAO-B enzymes. � 2023 Informa UK Limited, trading as Taylor & Francis Group.Item Synthesis and Evaluation of Antimicrobial Activity of N-Substituted Indole Derivatives and Molecular Docking Studies(Bentham Science Publishers, 2022-11-18T00:00:00) Dwivedi, Ashish Ranjan; Kumar, Vijay; Neha; Jangid, Kailash; Devi, Bharti; Kulharia, Mahesh; Kumar, Rakesh; Kumar, VinodThe increasing burden of microbial infection and emerging resistance against the available antimicrobial drugs drives the development of new agents. Two different series of indole-based compounds (VN-1 to VN-18) were synthesized and analyzed for antimicrobial activity by calculating the diameter of the inhibition zone using the broth dilution method and well diffusion method against Escherichia coli (E. coli) and environmental microbes. Most of the compounds displayed good to moderate activity against E. coli, and VN-4 and VN-9 displayed good inhibitory activity against the tested microbes. Molecular docking and binding energy calculation studies of all the synthesized compounds have been performed for targeting FabI, where most of the compounds showed significant interactions with the aromatic nicotin-amide moiety of NAD+. In molecular dynamics studies, VN-9 stays inside the binding cavity for sufficient time to induce antimicrobial activity. Thus, these indole-based derivatives may lead to the development of new antimicrobi-al agents that may act as FabI inhibitors. � 2022 Bentham Science Publishers.Item Design, synthesis and evaluation of 4-phenyl-1,2,3-triazole substituted pyrimidine derivatives as antiproliferative and tubulin polymerization inhibitors(Elsevier B.V., 2022-06-26T00:00:00) Dwivedi, Ashish Ranjan; Kumar, Vijay; Yadav, Ravi Prakash; Kumar, Naveen; Jangid, Kailash; Anand, Piyush; Sharma, Deepak Kumar; Barnawal, Somesh; Kumar, VinodLigands binding to the colchicine domain of the tubulin protein act as tubulin polymerization inhibitors and arrest the cell cycle in G2/M phase. A series of 4-Phenyl-1,2,3-triazole substituted pyrimidine derivatives have been synthesized and evaluated for antiproliferative and antitubulin activities. In the series, AV-6 and AV-14 were found to be active against the three tested cancer cell lines wherein AV-6 displayed IC50 values of 1.2 �M, 5.5 �M, and 1.9 �M while AV-14 displayed IC50 values of 4.7 �M, 1.7 �M, and 1.4 �M against HCT-116, MCF-7 and HT-29 cell lines, respectively. These compounds were found to be non toxic to the normal cells (HEK-293). In the cell cycle analysis and JC-1 studies, these compounds induce mitocondria mediated apoptosis. In the tubulin polymerization inhibition studies, AV-6 displayed significant tubulin polymerization inhibition potential. In the molecular docking and simulation studies, these compounds fit well in the active site of colchicine. � 2022 Elsevier B.V.Item Morpholine substituted quinazoline derivatives as anticancer agents against MCF-7, A549 and SHSY-5Y cancer cell lines and mechanistic studies(Royal Society of Chemistry, 2022-04-05T00:00:00) Dwivedi, Ashish Ranjan; Kumar, Vijay; Prashar, Vikash; Verma, Akash; Kumar, Naveen; Parkash, Jyoti; Kumar, VinodA series of morpholine substituted quinazoline derivatives have been synthesized and evaluated for cytotoxic potential against A549, MCF-7 and SHSY-5Y cancer cell lines. These compounds were found to be non-toxic against HEK293 cells at 25 ?M and hence display anticancer potential. In these series compounds, AK-3 and AK-10 displayed significant cytotoxic activity against all the three cell lines. AK-3 displayed IC50 values of 10.38 � 0.27 ?M, 6.44 � 0.29 ?M and 9.54 � 0.15 ?M against A549, MCF-7 and SHSY-5Y cancer cell lines. Similarly, AK-10 showed IC50 values of 8.55 � 0.67 ?M, 3.15 � 0.23 ?M and 3.36 � 0.29 ?M against A549, MCF-7 and SHSY-5Y, respectively. In the mechanistic studies, it was found that AK-3 and AK-10 inhibit the cell proliferation in the G1 phase of the cell cycle and the primary cause of death of the cells was found to be through apoptosis. Thus, morpholine based quinazoline derivatives have the potential to be developed as potent anticancer drug molecules. � 2022 RSCItem Role of peroxisome proliferator-activated receptor gamma (Ppar?) in different disease states: Recent updates(Bentham Science Publishers, 2020-07-17T00:00:00) Mal, Suvadeep; Dwivedi, Ashish Ranjan; Kumar, Vijay; Kumar, Naveen; Kumar, Bhupinder; Kumar, VinodPeroxisome proliferator-activated receptor (PPAR), a ligand dependant transcription factor, is a member of the nuclear receptor superfamily. PPAR exists in three isoforms i.e. PPAR alpha (PPAR?), PPAR beta (PPAR?), and PPAR gamma (PPAR?). These are multi-functional transcription factors and help in regulating inflammation, type 2 diabetes, lipid concentration in the body, metastasis, and tumor growth or angiogenesis. Activation of PPAR? causes inhibition of growth of cultured human breast, gastric, lung, prostate, and other cancer cells. PPAR? is mainly involved in fatty acid storage, glucose metabolism, and homeo-stasis and adipogenesis regulation. A large number of natural and synthetic ligands bind to PPAR? and modulate its activity. Ligands such as thiazolidinedione troglitazone, rosiglita-zone, pioglitazone effectively bind to PPAR?; however, most of these were found to display severe side effects such as hepatotoxicity, weight gain, cardiovascular complications and bladder tumor. Now the focus is shifted towards the development of dual-acting or pan PPAR ligands. The current review article describes the functions and role of PPAR? in various disease states. In addition, recently reported PPAR? ligands and pan PPAR ligands were dis-cussed in detail. It is envisaged that the present review article may help in the development of potent PPAR ligands with no or minimal side effects. � 2021 Bentham Science Publishers.Item Synthesis, Biological Evaluation and Molecular Modeling Studies of Propargyl‐Containing 2,4,6‐Trisubstituted Pyrimidine Derivatives as Potential Anti‐Parkinson Agents(Wiley, 2018) Kumar, Bhupinder; Kumar, Mohit; Dwivedi, Ashish Ranjan; Kumar, VinodMonoamine oxidase B (MAO‐B) inhibitors are potential drug candidates for the treatment of various neurological disorders including Parkinson's disease. A total of 20 new propargyl‐containing 2,4,6‐trisubstituted pyrimidine derivatives were synthesized and screened for MAO inhibition using Amplex Red assays. All the synthesized compounds were found to be reversible and selective inhibitors of the MAO‐B isoform at sub‐micromolar concentrations. MVB3 was the most potent MAO‐B inhibitor with an IC50 value of 0.38±0.02 μμ, whereas MVB6 (IC50=0.51±0.04 μμ) and MVB16 (IC50=0.48±0.06 μμ) were the most selective for MAO‐B with a selectivity index of more than 100‐fold. In cytotoxic studies, these compounds were found to be nontoxic to human neuroblastoma SH‐SY5Y cells at concentrations of 25 μm. MVB6 was found to decrease the intracellular level of reactive oxygen species to 68 % at 10 μm concentration, whereas other compounds did not produce significant changes in reactive oxygen species levels. In molecular modeling studies, MVB3 displayed strong binding affinity for the MAO‐B isoform with a dock score of −10.45, in agreement with the observed activity. All the compounds fitted well in the hydrophobic cavity of MAO‐B. Thus, propargyl‐substituted pyrimidine derivatives can be promising leads in the development of potent, selective and reversible MAO‐B inhibitors for the treatment of Parkinson's disease.Item Regioselective alkylation of 1,2,4-triazole using ionic liquids under microwave conditions(Walter de Gruyter GmbH, 2016) Kaur,Ramandeep; Kumar, Bhupinder; Dwivedi, Ashish Ranjan; Kumar, Vinod1-Substituted 1,2,4-triazole derivatives present in a large number of compounds and display a variety of bioactivities such as antibiotic, anti-inflammatory, anti-diabetic, antipsychotic, and anticancer. A regioselective protocol has been developed for the alkylation of 1,2,4- triazole using mild conditions. The 1-alkyl-1,2,4-triazole derivatives were synthesized under microwave conditions using potassium carbonate as a base and ionic liquid (hexylpyridinium bromide) as a solvent. The products were obtained in excellent yield, and the base-ionic liquid combination was recycled for a number of times. ? 2016 by De Gruyter 2016.Item Recent developments on 1,2,4-triazole nucleus in anticancer compounds: A review(Bentham Science Publishers B.V., 2016) Kaur, Ramandeep; Dwivedi, Ashish Ranjan; Kumar, Bhupinder; Kumar, Vinod1,2,4 triazole is an important nucleus present in a large number of compounds. More than thirty-five compounds containing this nucleus are introduced into the market. 1,2,4-triazole nucleus is stable to metabolism and acts as an important pharmacophore by interacting at the active site of a receptor as hydrogen bond acceptor and as a donor. Due to its polar nature, the triazole nucleus can increase the solubility of the ligand and it can significantly improve the pharmacological profile of the drug. A large number of 1,2,4-triazole derivatives are reported to possess a wide range of bioactivities including anti-cancer activity. This review article describes the role of 1,2,4-triazole nucleus in different types of anti-cancer agents such as nucleoside based anti-cancer agents, kinase inhibitors, tubulin modulators, aromatase and steroid sulfatase inhibitors, methionine aminopeptidase inhibitors, tankyrase inhibitors and metal complex based anti-cancer agents. It is expected that the current review article will provide insight into various ligand-receptor interactions and help in the rational design and development of novel 1,2,4-triazole based anti-cancer drugs with improved selectivity for cancer cells. ? 2016 Bentham Science Publishers.